AstraZeneca stock: Jefferies keeps GBp 17,500.00 target for AstraZeneca stock

Published on 10/21/2026 at 16:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca reports 9M and third-quarter results October 30, 2026. AstraZeneca stock costs EUR 150.53 on October 21, 2026 at Lang & Schwarz.

Jefferies keeps Buy rating

Jefferies maintained a Buy rating and a GBp 17,500.00 price target on October 20, 2026.
AstraZeneca will publish nine-month and third-quarter results on October 30, 2026.
AstraZeneca stock costs EUR 150.53 at Lang & Schwarz on October 21, 2026 at 4:36 p.m. CEST.
The company has a USD 261.9 billion market capitalization and a P/E ratio of 25.28.

Isometrische 3D-Grafik zeigt Labor, Produktion und Pharma-Logistikkette — AstraZeneca plc (ISIN GB0009895292) steuert eine komplexe Wertschöpfungskette von Forschung bis zur globalen Arzneimittel-Distribution, Illustration mit AI erstellt.

AstraZeneca PLC (ISIN GB0009895292) has a fresh analyst reference point: Markets Insider reported on October 20, 2026 that Jefferies analyst Michael Leuchten maintained a Buy rating and a GBp 17,500.00 price target. AstraZeneca was trading at EUR 150.53 at Lang & Schwarz on October 21, 2026 at 4:36 p.m. CEST.

Results date sets the next marker

AstraZeneca's investor-relations calendar lists nine-month and third-quarter 2026 results for October 30, 2026. The same calendar also schedules a Meet the Management event at ESMO for October 26, 2026, giving investors two dated milestones before the results release.

The timing matters because Jefferies' October 7 note expected third-quarter revenue about 1 percent ahead of Visible Alpha consensus and core earnings before interest and tax 3 percent above expectations. Proactive also reported that the broker expected AstraZeneca to reiterate its 2026 guidance.

US quote remains below yearly high

The Nasdaq quote stood at USD 168.86 on October 21, 2026 at 10:44 a.m. ET. Its 52-week range was USD 153.41 to USD 212.71, placing the quote USD 43.85 below the yearly high and USD 15.45 above the low. AstraZeneca is listed in London and on Nasdaq, according to Proactive.

Valuation and upcoming dates

AstraZeneca's market capitalization was USD 261.9 billion on October 21, 2026, while its price-to-earnings ratio was 25.28 and its trailing dividend yield was 2.00 percent. The company reported second-quarter 2026 revenue of USD 15.38 billion, operating profit of USD 3.16 billion and net income of USD 2.51 billion. Those figures give the October 30 results a clear numerical benchmark.

Stock position for investors

For investors, the key contrast is between a valuation that already reflects a large global biopharmaceutical business and a results date that can reset expectations. Jefferies' GBp 17,500.00 target and Buy rating provide the clearest recent external stance, while the upcoming release will test the operating figures behind that view.

Trading level and next milestone

AstraZeneca was trading at EUR 150.53 at Lang & Schwarz on October 21, 2026 at 4:36 p.m. CEST. The next dated company events are the October 26 ESMO management meeting and the October 30 nine-month and third-quarter results. The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.